Library Item - Page 8 of 792 Posts on Medivizor

Evaluating the effectiveness and safety of asciminib in real-world patients with chronic myeloid leukemia previously treated with ponatinib.

Posted by Medivizor on Apr 23, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of asciminib (Scemblix) in real-world patients with chronic myeloid leukemia (CML) previously treated with ponatinib (Iclusig). The data showed that asciminib treatment had promising effectiveness in these patients. Some background CML is a type of cancer that starts in blood-forming...

Evaluating the effectiveness of degarelix with or without apalutamide before prostate surgery in patients with high-risk prostate cancer.

Posted by Medivizor on Apr 23, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of degarelix (Firmagon) with or without apalutamide (Erleada) before radical prostatectomy (RP; prostate surgery) in patients with high-risk prostate cancer (PC). The data showed that degarelix plus apalutamide significantly improved the pathological response in these patients. Some background...

Evaluating whether there is an association between fertility treatments and the risk of breast cancer in women with a family history of breast cancer or with BRCA mutations.

Posted by Medivizor on Apr 23, 2023 in Infertility | 0 comments

In a nutshell This study evaluated whether fertility treatments increase the risk of breast cancer (BC) in women with a family history of BC or with BRCA mutations. The data showed that fertility treatments did not significantly increase the risk of BC in these women. Some background Treatment for infertility has become common, as people delay...

Evaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2– metastatic breast cancer.

Posted by Medivizor on Apr 23, 2023 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC). The data showed that SG significantly improved survival without cancer progression compared to chemotherapy in these...

Evaluating the safety and effectiveness of nivolumab and relatlimab before surgery in patients with resectable melanoma

Posted by Medivizor on Apr 15, 2023 in Melanoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of relatlimab (Opdualag) and nivolumab (Opdivo) combination therapy before surgery in patients with stages III and IV resectable melanoma. The study concluded that the relatlimab and nivolumab combination was safe and effective in these patients. Some background...

Can autologous cell therapy improve severe diabetic foot disease?

Posted by Medivizor on Apr 15, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the use of autologous cell therapy (ACT) to treat no-option chronic limb-threatening ischemia (NO-CLTI) in patients with diabetic patients. The study showed that compared to standard treatment, ACT resulted in a significant improvement in ischemia and food healing in these patients. Some background Diabetes...

Can BCT-100 be safely combined with low-dose cytarabine for older patients with acute myeloid leukemia that cannot receive intensive therapy?

Posted by Medivizor on Apr 15, 2023 in Leukemia | 0 comments

In a nutshell This study compared the effectiveness and safety of low-dose (LD) cytarabine (Ara-C; Cytosar-U) with recombinant arginase BCT-100 (BCT-100) to Ara-C alone in older patients with acute myeloid leukemia (AML) that were unsuitable for intensive therapy. The data showed that LD Ara-C (LDAC) combined with BCT-100 resulted in similar...

Is intermittent fasting safe and effective for individuals with insulin-treated type 2 diabetes?

Posted by Medivizor on Apr 15, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study investigated the safety and effectiveness of intermittent fasting (IF) for 3 non-consecutive days a week, over a period of 12 weeks in people with insulin-treated type 2 diabetes (T2D). The authors concluded that this dietary approach was safe and effective for controlling blood glucose, reducing total daily insulin requirements,...

Evaluating the effectiveness of an 8-week hypopressive exercise training program on urinary incontinence and pelvic floor muscle strength

Posted by Medivizor on Apr 15, 2023 in Urinary incontinence | 0 comments

In a nutshell The study evaluated the effectiveness of an 8-week hypopressive exercise training program on urinary incontinence (UI) and pelvic floor muscle strength. The data found that hypopressive exercise training improved pelvic floor muscle strength and UI symptoms in these patients. Some background Pelvic floor dysfunction is a common...

Evaluating the effectiveness of immunomodulators in reducing cardiovascular events in patients with rheumatoid arthritis

Posted by Medivizor on Apr 15, 2023 in Rheumatoid Arthritis | 0 comments

In a nutshell The study evaluated the effectiveness of reducing cardiovascular events (CVE) with immunomodulatory (IM) in patients with rheumatoid arthritis (RA). The main finding was that IM showed improvements in vascular inflammation in this group of patients. Some background IMs are drugs that modify the immune system to help the body respond...

How safe and effective is orally delivered insulin for patients with early-stage type 2 diabetes?

Posted by Medivizor on Apr 15, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study compared the safety and effectiveness of different doses of an oral insulin capsule formulation (Capsulin™) to patients with early-stage type 2 diabetes (T2D). The data showed that twice-daily, orally administered Capsulin at a dose of 150 international units (IU) was safe and resulted in a significant lowering...

Can vitamin B12 supplementation improve the symptoms of diabetic peripheral neuropathy in patients with diabetes?

Posted by Medivizor on Apr 15, 2023 in Diabetes mellitus | 0 comments

In a nutshell This review assessed the effect of vitamin B12 supplementation on clinical outcomes when used alone or combined with other treatments for diabetic peripheral neuropathy (PN). The authors concluded that a greater reduction of PN symptoms occurred with the use of B12 supplementation alone or in combination with other treatments compared to...

Library Item Posts on Medivizor

Evaluating the effectiveness and safety of asciminib in real-world patients with chronic myeloid leukemia previously treated with ponatinib.

Evaluating the effectiveness of degarelix with or without apalutamide before prostate surgery in patients with high-risk prostate cancer.

Evaluating whether there is an association between fertility treatments and the risk of breast cancer in women with a family history of breast cancer or with BRCA mutations.

Evaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2– metastatic breast cancer.

Evaluating the safety and effectiveness of nivolumab and relatlimab before surgery in patients with resectable melanoma

Can autologous cell therapy improve severe diabetic foot disease?

Can BCT-100 be safely combined with low-dose cytarabine for older patients with acute myeloid leukemia that cannot receive intensive therapy?

Is intermittent fasting safe and effective for individuals with insulin-treated type 2 diabetes?

Evaluating the effectiveness of an 8-week hypopressive exercise training program on urinary incontinence and pelvic floor muscle strength

Evaluating the effectiveness of immunomodulators in reducing cardiovascular events in patients with rheumatoid arthritis

How safe and effective is orally delivered insulin for patients with early-stage type 2 diabetes?

Can vitamin B12 supplementation improve the symptoms of diabetic peripheral neuropathy in patients with diabetes?

Categories

Recent Posts

Archives

Library Item Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email